- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03458130
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
Study Overview
Status
Intervention / Treatment
Detailed Description
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy.
The primary objective of this study is to evaluate the safety and tolerability of AG10 administered to adult patients with symptomatic transthyretin amyloid cardiomyopathy (ATTRCM).
This study will be a Phase 2, randomized, placebo-controlled, dose-ranging study in 45 male and/or female patients with symptomatic ATTR-CM aged 18 through 90 years.
If all doses are well tolerated, the duration of each patient's participation in the study will be 28 days of treatment. In addition, there will be a 28-day screening period before treatment and a 30-day follow-up period before the final Follow-up Visit.
This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK and PD of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening and randomization will be followed by a 28-day blinded, placebo-controlled treatment period. secondary objectives of this study are: to characterize the pharmacokinetics (PK) of AG10 administered orally twice daily in patients with symptomatic ATTRCM, and to describe the pharmacodynamic (PD) properties of AG10 as assessed by established assays of transthyretin (TTR) stabilization, including Fluorescent Probe Exclusion (FPE) assay and Western blot, and to describe the Pharmacokinetic Pharmacodynamic (PKPD) relationship of AG10 in adult patients with symptomatic ATTRCM.
Eligible patients will be randomized in a 1:1:1 ratio to placebo or one of two different doses of AG10 administered twice daily. A minimum of 30% of patients enrolled will be mutant ATTR-CM.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Cedars-Sinai Medical Center
-
Palo Alto, California, United States, 94304
- Stanford University
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02127
- Boston University
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
South Carolina
-
Charleston, South Carolina, United States, 29424
- Medical University of South Carolina
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
- Be a male or female ≥18 to ≤90 years of age.
- Have an established diagnosis of ATTR-CM with either wild-type transthyretin or a variant transthyretin genotype (assessed by genotyping, with patients with concurrent monoclonal gammopathy of undetermined significance requiring a confirmatory test using mass spectrometry) as defined by either positive endomyocardial biopsy or positive technetium pyrophosphate scan.
- Have a history of heart failure evidenced by at least one prior hospitalization for heart failure or clinical evidence of heart failure (without hospitalization) requiring medical management.
- Have New York Heart Association (NYHA) Class II-III symptoms.
- Male patients and female patients of childbearing potential who engage in heterosexual intercourse must agree to use appropriate method(s) of contraception.
- For patients taking cardiovascular medical therapy, with the exception of diuretic dosing, must be on stable doses (defined as no greater than 50% dose adjustment and no categorical changes of medications) for at least 2 weeks prior to Screening.
Exclusion Criteria:
- Acute myocardial infarction, acute coronary syndrome or coronary revascularization within 90 days prior to Screening.
- Experienced stroke within 90 days prior to Screening.
- Has hemodynamic instability at Screening or Randomization that, in the judgment of the Principal Investigator (PI), would pose too great a risk for participation in the study.
- Has estimated glomerular filtration rate (GFR) <30 mL/min/1.73 m2 at Screening.
- Is likely to undergo heart transplantation within the next year.
- Has confirmed diagnosis of light-chain amyloidosis.
- Has abnormal liver function tests at Screening, defined as Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3 × upper limit of normal (ULN) or total bilirubin >2 × ULN.
- Has abnormalities in clinical laboratory tests at Screening or Randomization that, in the judgment of the PI, would pose too great a risk for participation in the study.
- Known hypersensitivity to study drug (AG10 or placebo), its metabolites, or formulation excipient
- Current treatment with diflunisal, tafamidis, green tea, doxycycline, tauroursodeoxycholic acid (TUDCA)/Ursodiol, Patisiran or Inotersen within 14 days or 5 half-lives of the prior investigational agent (whichever is longer) prior to Screening.
- Females who are pregnant or breastfeeding. Lactating females must agree to discontinue nursing before the study drug is administered. A negative serum pregnancy test at Screening and a negative urine pregnancy test at Randomization visit are required for female patients of childbearing potential.
- In the judgment of the investigator, has any clinically significant ongoing medical condition that might jeopardize the patient's safety or interfere with the study, including participation in another investigational drug or investigational device study within the 30 days prior to Screening with potential residual effects that might confound the results of this study.
- Has any laboratory abnormality or condition that, in the investigator's opinion, could adversely affect the safety of the patient or impair the assessment of study results.
- Has any condition that, in the opinion of the investigator, would preclude compliance with the study protocol such as a history of substance abuse, alcoholism or a psychiatric condition.
- Has participated in another investigational study within 14 days or 5 half-lives of the prior investigational agent (whichever is longer) prior to screening. Exceptions can be made in the case of observational and/or registry studies upon consultation with the Medical Monitor.
- Current treatment with, or chronic use of, a proton pump inhibitor (PPI) or histamine-receptor 2 (H2) antagonist within 14 days or 5 half-lives of the prior agent (whichever is longer) prior to Screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: AG10 Low Dose
AG10 400mg tablets twice daily for 28 days
|
TTR stabilizer
|
ACTIVE_COMPARATOR: AG10 High Dose
AG10 800mg tablets twice daily for 28 days
|
TTR stabilizer
|
PLACEBO_COMPARATOR: Placebo
Placebo tablets twice daily for 28 days
|
Nonactive control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Diastolic Blood Pressure
Time Frame: Baseline to Day 28
|
Change in Diastolic Blood Pressure from Baseline to Day 28 (Postdose)
|
Baseline to Day 28
|
Change in Heart Rate
Time Frame: Baseline to Day 28
|
Change in Heart Rate from Baseline to Day 28 (Postdose)
|
Baseline to Day 28
|
Change in Respiratory Rate
Time Frame: Baseline to Day 28
|
Change in Respiratory Rate from Baseline to Day 28 (Postdose)
|
Baseline to Day 28
|
Change in Temperature
Time Frame: Baseline to Day 28
|
Change in Temperature from Baseline to Day 28
|
Baseline to Day 28
|
Change in Systolic Blood Pressure
Time Frame: Baseline to Day 28
|
Change in Systolic Blood Pressure from Baseline to Day 28
|
Baseline to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Threshold Levels of Overall % Stabilization >= 95% and >= 99% by Fluorescent Probe Exclusion (FPE)
Time Frame: Day 1 to Day 28
|
In specialized lab tests on patient samples that measure the stability of the healthy form of TTR, both doses of AG10 were able to reach near complete stabilization.
|
Day 1 to Day 28
|
Pharmacokinetic (PK): Steady State Trough Concentration of AG10
Time Frame: Day 14 and Day 28
|
Non-fluctuating minimal amount of AG10 in blood at Day 14 and Day 28
|
Day 14 and Day 28
|
Collaborators and Investigators
Investigators
- Study Director: MARK MCGOVERN, RN, Eidos Therapeutics, a BridgeBio company
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AG10-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial ATTR-CM (ATTRm-CM, or FAC)
-
PfizerCompletedATTR-CM | TTR-CMUnited States
-
Ionis Pharmaceuticals, Inc.AstraZenecaActive, not recruitingTransthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)United States, Spain
-
Taichung Veterans General HospitalRecruiting
-
University of EdinburghBritish Heart Foundation; Netherlands Heart Foundation; Deutsches Zentrum für...Recruiting
-
Ensho Health Intelligent Systems Inc.Enrolling by invitationTransthyretin Amyloid Cardiomyopathy ("ATTR-CM")Canada
-
Ionis Pharmaceuticals, Inc.AstraZenecaActive, not recruitingTransthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)United States, United Kingdom, Italy, Spain
-
PfizerRecruitingATTR-CM (Transthyretin Amyloid Cardiomyopathy)Korea, Republic of
-
Novo Nordisk A/SActive, not recruitingTransthyretin Amyloid Cardiomyopathy (ATTR CM)United States, Netherlands, Spain, Portugal, Canada, Czechia, France, Germany, Italy, Japan
-
Novo Nordisk A/SRecruitingTransthyretin Amyloid Cardiomyopathy (ATTR CM)United States, Netherlands, Germany, Canada, Czechia, France, Italy, Portugal, Spain
Clinical Trials on AG10
-
Eidos Therapeutics, a BridgeBio companyActive, not recruitingAmyloid Cardiomyopathy, Transthyretin-RelatedUnited States, Spain, Australia, Canada, Italy, Netherlands, Ireland, New Zealand, Belgium, Israel, Greece, Korea, Republic of, Czechia, Brazil, Denmark, Portugal, United Kingdom
-
Eidos Therapeutics, a BridgeBio companyWithdrawnTransthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
-
Eidos Therapeutics, a BridgeBio companyWithdrawnTransthyretin-Related (ATTR) Familial Amyloid PolyneuropathyUnited States
-
Eidos Therapeutics, a BridgeBio companyCompleted
-
Alexion Pharmaceuticals, Inc.Eidos Therapeutics, a BridgeBio companyActive, not recruitingSymptomatic Transthyretin Amyloid CardiomyopathyJapan
-
Eidos Therapeutics, a BridgeBio companyActive, not recruiting
-
Alexion PharmaceuticalsCelerionCompleted
-
Eidos Therapeutics, a BridgeBio companyCelerionCompletedAmyloid Cardiomyopathy, Transthyretin-RelatedUnited States
-
Eidos Therapeutics, a BridgeBio companyCompletedHeart Diseases | Amyloidosis | Cardiomyopathies | Transthyretin Amyloidosis | Amyloid CardiomyopathyUnited States, Netherlands, Ireland, Canada, Italy, Spain, Belgium, New Zealand, Israel, Australia, Portugal, Brazil, Poland, Czechia, Denmark, Greece, Korea, Republic of, United Kingdom